Durvalumab [1428935-60-7]

TargetMol Chemicals

Durvalumab

10

1428935-60-7

Antibody

Research Use Only

Durvalumab

SDS-PAGE:97.2%;SEC-HPLC:95.3%

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

3 years

-20°C

12352203